ArticlePloS one2018
Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy.BMC cardiovascular disorders · 2024Pooled it
- Hypertrophic Cardiomyopathy in Saudi Arabia: A Systematic Review of the Epidemiological, Clinical, and Imaging Features.Current cardiology reviews · 2023Pooled it
- Article
- Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data.ESC heart failure · 2026Observational
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- Clinical and economic burden associated with symptomatic and asymptomatic obstructive hypertrophic cardiomyopathy in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Observational
- Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2026Article
- Effectiveness of radiofrequency catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: long-term outcomes and predictors of recurrence.Cardiovascular diagnosis and therapy · 2026Article
- Left Atrial Appendage Thrombus in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: Prevalence and Risk Factors.Journal of the American Heart Association · 2026Article
- What Do We Know About Hypertrophic Cardiomyopathy in Poland in the Period 2016-2021 Based on Data From the Public Health System?International journal of public health · 2026Article
- Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy.Journal of medical economics · 2025Article
- Secondary Findings from Exome Sequencing of a Greek Cohort.Current issues in molecular biology · 2025Article
- Prevalence, Patient Characteristics, and Treatment of Patients with Hypertrophic Cardiomyopathy: A Nationwide Payer Database Study.Cardiology and therapy · 2025Article
- Observational
- Associations of sex on economic burden in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from medical and pharmacy claims data.Frontiers in cardiovascular medicine · 2025Article
- Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Nature cardiovascular research · 2024Article
- Extended septal myectomy versus alcohol septal ablation: clinical results at a national referral centre.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- Sudden cardiac death during scuba diving: a case report of a patient with unknown hypertrophic cardiomyopathy.European heart journal. Case reports · 2024Article
- Clinical utility of electrocardiographic voltage parameters for the diagnosis of hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2024Article
- Clinical burden of obstructive hypertrophic cardiomyopathy in France.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. Reported prevalence rates vary substantially between 1:500 (0.2%) and 1:3,000 (0.03%), which may be attributed to different study designs and population characteristics. Prevalence data for Germany is not available. Consequently, this study aimed (1) to quantify age- and gender-specific clinically diagnosed HCM prevalence in Germany based on the analysis of health care claims data of > 5 million insurants in 2015, and (2) to analyze temporal prevalence trends from 2011 to 2015.
methodsData were extracted from the InGef (Insitute for Applied Health Research) database, which is an anonymized healthcare claims database with longitudinal data from patients insured in one of approximately 70 German social health insurances (SHIs). Patients were classified as HCM prevalent, if they had at least one verified ambulatory or one hospital main- or secondary discharge diagnosis of HCM (I42.1 or I42.2).
resultsIn 2015, HCM was prevalent in 4,000 out of 5,490,810 patients (0.07%; 1:1,372). HCM prevalence increased gradually with age from 7.4/100,000 persons (95% CI 5.2-10.1) in 0-9 years old to 298.7/100,000 persons (95% CI 276.4-322.4) in patients > 80 years. In all age categories, men had a numerically higher prevalence than women with significant differences in patients > 30 years. There was a gradual annual prevalence increase from 75.8 (95% CI 75.2-76.4) in 2011 to 84.2 (95% CI 83.5-84.8) in 2015 per 100,000 persons.
conclusionsOverall, prevalence of clinically diagnosed HCM in Germany is lower than in systematic population studies based on echocardiographic diagnosis. Prevalence increased with advancing age and showed a constant yearly rise. Those observations may improve our understanding of the burden of this genetic heart disease on the health care system in Germany, increase the diagnostic awareness among clinicians and shape future screening and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.